Conditions: Multiple Myeloma
Keywords: Revlimid progression free Lenalidomide
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 42
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine in a phase II trial, whether further maintenance therapy with Revlimid can extend the duration of progression-free survival and the duration of complete or near complete response compared to no further therapy beyond the TT3 protocol-prescribed 3 years of maintenance with 1 year of VTD plus 2 years with TD, 3 years with VTD (2003-33) or VRD (2006-66).

Detailed description:
Determine the associated toxicities in qualitative and quantitative terms using NCI CTCAE(NCI common terminology for adverse events)

Arms:
arm 1: Revlimid dosing will be in the morning at the same time each day arm 2: No treatment control.

Interventions: intervention 1: Revlimid
Intervention descriptions: intervention 1: 10 mg/day in the morning same time each day

Protocol document: